{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:34:54Z","timestamp":1773084894869,"version":"3.50.1"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"09","funder":[{"name":"Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University","award":["2022-LCYJ-PY-20"],"award-info":[{"award-number":["2022-LCYJ-PY-20"]}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2415000"],"award-info":[{"award-number":["2023YFC2415000"]}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073367"],"award-info":[{"award-number":["82073367"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:p>\n            Background\u2009Hemophilia A (HA) is an inherited bleeding disorder caused by a deficiency or defect in factor VIII (FVIII).<\/jats:p><jats:p>\n            Methods\u2009We investigated the role of clot waveform analysis (CWA) of activated partial thromboplastin time in the diagnosis and therapeutic monitoring of HA. The changes in CWA parameters the maximum clotting velocity (|Min1|), maximum clotting acceleration (|Min2|), and maximum clotting deceleration (|Max2|) were detected among mild, moderate, and severe HA groups.<\/jats:p><jats:p>\n            Results\u2009As the severity of HA subtypes increased, the levels of |Min1|, |Min2|, and |Max2| progressively decreased (p\u2009&lt;\u20090.05). Receiver operating characteristic curve analysis showed that |Max2| and |Min2| were more effective than |Min1| in distinguishing different types of HA patients, with higher diagnostic efficacy. The standard curves based on Actin FSL reagent for normal and low levels of FVIII:C-|Max2| were established, with R2 values of 0.98 and 0.99, respectively. These curves can be utilized for monitoring during replacement therapies involving full-length recombinant FVIII and B-domain-deleted FVIII. Thirty cases of HA patients utilized the FVIII-|Max2| standard curve to obtain individual pharmacokinetics characteristic parameters. The clearance, half-life (t1\/2), time to FVIII:C of 1% above baseline (tt1%), and predicted dosage showed no statistically significant differences compared with one-stage assay (p\u2009&gt;\u20090.05).<\/jats:p><jats:p>\n            Conclusion\u2009CWA is an economical and practical tool, and its related parameters are associated with the severity of HA. It has promising clinical prospects in predicting FVIII:C levels and individualized treatment when HA patients undergo replacement therapy.<\/jats:p>","DOI":"10.1055\/s-0044-1786029","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T23:28:02Z","timestamp":1713310082000},"page":"852-860","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Clot Waveform Analysis and Related Parameters in the Diagnosis and Treatment of Hemophilia A"],"prefix":"10.1055","volume":"124","author":[{"given":"Guanghao","family":"Song","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangbin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"E Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.17677","article-title":"Current status of haemophilia inhibitor management in Mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices","volume":"194","author":"W Liu","year":"2021","journal-title":"Br J Haematol"},{"issue":"S 06","key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0035-1552563","article-title":"Individualizing factor replacement therapy in severe hemophilia","volume":"41","author":"M D Carcao","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0032-1319768","article-title":"Quality standards for sample processing, transportation, and storage in hemostasis testing","volume":"38","author":"D M Adcock Funk","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/srep03868","article-title":"Effects of storage time and temperature on coagulation tests and factors in fresh plasma","volume":"4","author":"L Feng","year":"2014","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1076029620912027","DOI":"10.1177\/1076029620912027","article-title":"Update on the clot waveform analysis","volume":"26","author":"H Wada","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/jth.12287","article-title":"Towards standardization of clot waveform analysis and recommendations for its clinical applications","volume":"11","author":"M Shima","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ijlh.12724","article-title":"Clot waveform analysis: where do we stand in 2017?","volume":"39","author":"P O Sevenet","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"K Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/hae.14350","article-title":"Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A","volume":"27","author":"F Xue","year":"2021","journal-title":"Haemophilia"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/hae.13540","article-title":"Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT\u00ae","volume":"24","author":"M E Mingot-Castellano","year":"2018","journal-title":"Haemophilia"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.acc.2019.01.006","article-title":"A practical guide to validation and verification of analytical methods in the clinical laboratory","volume":"90","author":"J Pum","year":"2019","journal-title":"Adv Clin Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jth.12220","article-title":"Systems biology of coagulation","volume":"11","author":"S L Diamond","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"S 01","key":"ref16","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.5482\/HAMO-14-02-0016","article-title":"Clot waveform analysis in patients with haemophilia A","volume":"34","author":"T Siegemund","year":"2014","journal-title":"Hamostaseologie"},{"issue":"02","key":"ref17","first-page":"020710","article-title":"Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism","volume":"29","author":"C W Tan","year":"2019","journal-title":"Biochem Med (Zagreb)"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/1076029617724230","article-title":"An evaluation of the activated partial thromboplastin time waveform","volume":"24","author":"T Matsumoto","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1111\/hae.13266","article-title":"Clot waveform analysis using CS-2000i\u2122 distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A","volume":"23","author":"T Matsumoto","year":"2017","journal-title":"Haemophilia"},{"issue":"14","key":"ref20","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3390\/diagnostics13142447","article-title":"Reagent effects on the activated partial thromboplastin time clot waveform analysis: a multi-centre study","volume":"13","author":"W H Wong","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ijlh.12975","article-title":"Optimal wavelength for the clot waveform analysis: determination of the best resolution with minimal interference of the reagents","volume":"41","author":"J Evrard","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12185-022-03419-4","article-title":"Activated partial thromboplastin time-based clot waveform analysis enables measurement of very low levels of factor IX activity in patients with severe hemophilia B","volume":"116","author":"A Nishiyama","year":"2022","journal-title":"Int J Hematol"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12185-016-2108-x","article-title":"A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity","volume":"105","author":"T Matsumoto","year":"2017","journal-title":"Int J Hematol"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0040-1715838","article-title":"A novel assessment of factor VIII activity by template matching utilizing weighted average parameters from comprehensive clot waveform analysis","volume":"121","author":"N Shimonishi","year":"2021","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3343\/alm.2023.43.6.531","article-title":"Clot waveform analysis for hemostatic abnormalities","volume":"43","author":"H Wada","year":"2023","journal-title":"Ann Lab Med"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1538-7836.2006.01730.x","article-title":"The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay","volume":"4","author":"T Matsumoto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.13168","article-title":"Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study","volume":"23","author":"A Hillarp","year":"2017","journal-title":"Haemophilia"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/hae.13897","article-title":"An overview of turoctocog alfa pegol (N8-GP; ESPEROCT\u00ae ) assay performance: implications for postadministration monitoring","volume":"26","author":"M Ezban","year":"2020","journal-title":"Haemophilia"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1055\/s-0037-1613023","article-title":"The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C)","volume":"87","author":"M Shima","year":"2002","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/hae.12492","article-title":"New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients","volume":"20","author":"M Milos","year":"2014","journal-title":"Haemophilia"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/IJPM.IJPM_336_19","article-title":"Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in hemophilia A","volume":"64","author":"R G Dave","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ijlh.13347","article-title":"Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype","volume":"43","author":"M Milos","year":"2021","journal-title":"Int J Lab Hematol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1786029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:45:25Z","timestamp":1730803525000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1786029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":32,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2024,8,27]]},"published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1786029","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}